Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Turnstone Biologics Corp - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
TSBX
Nasdaq
2836
https://www.turnstonebio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Turnstone Biologics Corp
Turnstone Biologics Appoints William Waddill to its Board of Directors
- Apr 16th, 2024 1:00 pm
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
- Mar 21st, 2024 9:06 pm
Turnstone Biologics Corp. (NASDAQ:TSBX) institutional investors have had a good week as stock gains 34%
- Mar 2nd, 2024 1:25 pm
Turnstone Biologics to Participate in Upcoming Investor Conferences
- Feb 21st, 2024 11:00 am
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
- Feb 20th, 2024 10:00 pm
Here's Why Turnstone Biologics (NASDAQ:TSBX) Must Use Its Cash Wisely
- Jan 21st, 2024 2:15 pm
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
- Nov 27th, 2023 11:00 am
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
- Nov 10th, 2023 2:49 am
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Nov 3rd, 2023 10:00 am
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
- Oct 30th, 2023 10:00 am
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Sep 28th, 2023 10:00 am
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
- Sep 1st, 2023 9:57 pm
Steven Cohen's Q2 2023 13F Filing Update: Top Trades and Portfolio Overview
- Aug 15th, 2023 12:41 am
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
- Jul 21st, 2023 6:15 am
Scroll